TRAF2 and cancer: TRAF2 loss was found to be significantly enriched in responders in the overall pan-cancer cohort (p = 1.8 × 10−4), as well as urothelial cancer (p = 8.0 × 10−3), melanoma (p = 3.2 × 10−2), and borderline nonsignificance in the “other tumor types” cohort (p = 7.0 × 10−2) as individual cohorts (Figure 5D).